Alfa Farmacéutica, SA – Trademark Portfolio

Entity Type: 99

Alfa Farmacéutica, SA holds 1 U.S. trademark filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 32 (Light Beverages) — 1 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 2 Nice Classification classes. Currently, 1 trademark is registered. Notable registered marks include LEVUSOL. The owner is based in Guatemala City.

Avenida Petapa, 15-77 Zona 12

Guatemala City 01012 , GT

1 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

LEVUSOL
LEVUSOL
Registered 2023

Trademark Classifications

Alfa Farmacéutica, SA's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

32
Light Beverages (1 filing)

Beers; mineral and aerated waters and other non-alcoholic beverages; fruit beverages

5
Pharmaceuticals (1 filing)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does Alfa Farmacéutica, SA have?

Alfa Farmacéutica, SA has 1 U.S. trademark filed with the USPTO. Of these, 1 registered.

What trademark classes does Alfa Farmacéutica, SA file in?

Alfa Farmacéutica, SA files trademarks across 2 Nice Classification classes. The most active classes are Class 32 (Light Beverages), Class 5 (Pharmaceuticals). Class 32 covers beers; mineral and aerated waters and other non-alcoholic beverages; fruit beverages.

What are Alfa Farmacéutica, SA's most well-known trademarks?

Alfa Farmacéutica, SA's registered trademark portfolio includes well-known marks such as LEVUSOL. These are among 1 currently registered trademark in the portfolio.

What is Alfa Farmacéutica, SA's trademark registration success rate?

Alfa Farmacéutica, SA has a 100% trademark registration rate, with 1 out of 1 resolved applications resulting in successful registration. Currently, 0 applications are pending review.